作者: Helen Dakin , Carrie Fidler , Christie Harper
DOI: 10.1111/J.1524-4733.2010.00777.X
关键词: Viral hepatitis 、 Hepatitis B 、 Medicine 、 Hepatitis B virus 、 Immunology 、 HBeAg 、 Telbivudine 、 Adefovir 、 Lamivudine 、 Entecavir 、 Internal medicine 、 Gastroenterology
摘要: Abstract Background/aims Five nucleoside/nucleotide treatments are now available for chronic hepatitis B (CHB). This meta-analysis aimed to assess the relative efficacy of adefovir, entecavir, lamivudine, telbivudine, tenofovir disoproxil fumarate (TDF), and nucleos(t)ide combinations in treatment CHB. Methods A systematic review MEDLINE Cochrane library was conducted identify all studies evaluating these nucleos(t)ides adults with Randomized controlled trials were included if they reported proportion patients undetectable virus (HBV) DNA or e antigen (HBeAg) loss/seroconversion at 1 year. Bayesian mixed comparison meta-analyses WinBUGS efficacy. Results random-effects on treatment-naive HBeAg-positive CHB demonstrated that 94% will achieve HBV Conclusions In nucleos(t)ide-naive CHB, TDF is associated highest probability achieving year considered.